After Heat Biologics (HTBX) announced plans for a Phase 1b trial investigating the combination of its HS-110 vaccine and Bristol-Myers' (BMY) PD-1 inhibitor nivolumab in non-small cell lung cancer and said it is winding down its ongoing Phase 2 trial with HS-110 that does not include a checkpoint inhibitor combination, Cantor Fitzgerald analyst Mara Goldstein called the decision a positive. The new course preserves the current timeline and cash while making the clinical program more relevant to the evolving standard of care, according to Goldstein, who keeps a Buy rating and $18 price target on Heat Biologics shares.